All In Biotech

NDA 017377 · Sun Pharm Industries

Bactrim

Sulfamethoxazole, Trimethoprim · Oral · Sulfonamide Antimicrobial; Dihydrofolate Reductase Inhibitor Antibacterial

Discontinued

Last checked: Nov 19, 2026Latest source record: Feb 21, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1973

Jul 30, 1973

Approved uses

3

Original approval plus efficacy supplements

Registered trials

235

70 Phase 3, 31 recruiting

FAERS reports

82,621

68,122 serious, 10,051 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Dec 30, 2024.

INDICATIONS AND USAGE To reduce the development of drug-resistant bacteria and maintain the effectiveness of BACTRIM (sulfamethoxazole and trimethoprim) tablets and other antibacterial drugs, BACTRIM (sulfamethoxazole and trimethoprim) tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to empiric selection of therapy. Urinary Tract Infections For the treatment of urinary tract infections due to susceptible strains of the following organisms: Escherichia coli , Klebsiella species, Enterobacter species, Morganella morganii , Proteus mirabilis and Proteus vulgaris . It is recommended that initial episodes of uncomplicated urinary tract infections be treated with a single effective antibacterial agent rather than the combination. Acute Otitis Media For the treatment of acute otitis media in pediatric patients due to susceptible strains of Streptococcus pneumoniae or Haemophilus influenzae when in the judgment of the physician sulfamethoxazole and trimethoprim offers some advantage over the use of other antimicrobial agents. To date, there are limited data on the safety of repeated use of BACTRIM in pediatric patients under two years of age. BACTRIM is not indicated for prophylactic or prolonged administration in otitis media at any age. Acute Exacerbations of Chronic Bronchitis in Adults For the treatment of acute exacerbations of chronic bronchitis due to susceptible strains of Streptococcus pneumoniae or Haemophilus influenzae when a physician deems that BACTRIM could...

Therapeutic areas: Infectious disease and vaccines

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jun 15, 1990 Supplement 40 · Efficacy
  • Feb 23, 1982 Supplement 32 · Efficacy
  • Jul 30, 1973 Original approval · Type 5 - New Formulation or New Manufacturer
2 products under this application
  • BACTRIM · SULFAMETHOXAZOLE 400MG; TRIMETHOPRIM 80MG · TABLET, ORAL · Discontinued · TE AB
  • BACTRIM DS · SULFAMETHOXAZOLE 800MG; TRIMETHOPRIM 160MG · TABLET, ORAL · Discontinued · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Sulfamethoxazole" as an intervention, any sponsor and status, largest first.

All 235 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • pyrexia6,152
  • fatigue5,186
  • off label use4,973
  • diarrhoea4,859
  • nausea4,706
  • rash4,407
  • dyspnoea4,168
  • pain3,891
  • vomiting3,691
  • drug ineffective3,561
  • pneumonia3,281
  • drug hypersensitivity3,242

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004996
20051,106
20061,208
20071,353
20081,698
20091,821
20101,873
20112,415
20122,506
20131,853
20142,394
20153,981
20164,832
20174,805
20186,106
20196,736
20206,607
20215,912
20225,294
20235,169
20245,500
20254,959
20263,491

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Bactrim (Sulfamethoxazole/Trimethoprim)

2024 spending

$2K

Beneficiaries

18

36 claims

Per beneficiary

$99

$1.17 per unit

View as table
YearSpending
2020$2,067
2021$1,861
2022$0
2023$1,593
2024$1,780

Part D: Bactrim Ds (Sulfamethoxazole/Trimethoprim)

2024 spending

$23K

Beneficiaries

230

335 claims

Per beneficiary

$100

$2.49 per unit

View as table
YearSpending
2020$28,371
2021$19,870
2022$16,941
2023$18,548
2024$23,058

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,025 on PubMed

Sponsor: Sun Pharm Industries · Also marketed as Bactrim Ds

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.